Security key
98422T100
CUSIP: 98422T100
Security key
98422T100
Report period
Q2 2025
Institutions
35
Top holders
10
Broader feeds
Reporting periods
Recent filing periods:
Ownership snapshot
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Rank 1 holder
Rank 2 holder
Rank 3 holder
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| AbbVie Inc. |
13D/G
|
9%
|
$3,304,348
4,347,826 shares
|
$0 | 11 Feb 2025 |
| GILEAD SCIENCES, INC. |
13F
Company
|
142%
|
$6,595,989
9,105,451 shares
|
— | 31 Mar 2025 |
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
Company · 10%+ Owner
|
71%
|
$3,308,202
4,566,817 shares
|
— | 31 Mar 2025 |
| Merck & Co., Inc. |
13F
Company
|
23%
|
$1,074,834
1,483,758 shares
|
— | 31 Mar 2025 |
| TAKEDA PHARMACEUTICAL CO LTD |
3/4/5
13F
10%+ Owner · Company
|
23%
from 13F
|
$1,224,350
1,475,121 shares
|
— | 26 Oct 2021 |
| MORGAN STANLEY |
13F
Company
|
18%
|
$837,289
1,155,838 shares
|
— | 31 Mar 2025 |
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Investor-level positions for this CUSIP, loaded as an interactive table.
| Investor | Option | Weight % | Change % | Reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* Reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that failed the local validity check.
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).